| abstract |
Preferably, a vaccine used for the prophylaxis or treatment of interleukin 23 (IL-23) related diseases, comprising a peptide conjugated to a pharmaceutically acceptable carrier, said peptide being QPEGHHWETQQIPSLS (SEQ ID NO: 103; p8322). ), QPEGHHWETQ (SEQ ID NO: 98; p8461), TQQIPSLSPSQ (SEQ ID NO: 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID NO: 100; p9269), QPEGHHWETQQIPSLSSPS (SEQ ID NO: 101; p9440), and QPEGHHWETQQIPSQQQHQQH (SEQ ID NO: 103; p8322), wherein the IL-23-related disease is psoriasis, psoriatic Inflammation, rheumatoid arthritis, systemic lupus erythematosus, diabetes, preferably type I diabetes, atherosclerosis, inflammatory bowel disease (IBD) / Crohn's disease, multiple sclerosis, Behcet's disease, ankylosing spondylitis, Forked Koyanagi・ Harada disease, chronic granulomatosis, purulent scab, anti-neutrophil cytoplasmic antibody (ANCA) related vasculitis, neurodegenerative disease, preferably Alzheimer's disease or multiple sclerosis, atopic dermatitis, graft versus host Disease, cancer, preferably selected from the group of esophageal cancer, colon cancer, lung adenocarcinoma, small cell cancer, and oral squamous cell carcinoma, in particular psoriasis, neurodegenerative disease or IBD, Disclose a vaccine. |